SecBot SecBot

GRFS

Grifols SA
Nasdaq· Pharmaceutical Preparations· CIK 0001438569 Biotech & Drug Discovery
$8.73 +0.04 (+0.46%)
Nov 16 4:00 PM ET · prev $8.69
Market cap
$6.1B
Mid cap
Consensus
Buy
67% Buy or better · 21 analysts
Median target
$10.37
+19% · range $9.00–11.73
1 year
+2.7%
from $8.50 · Nov 17
30 days
+14.3%
from $7.64
52-week range
$7.02–9.72
−10% from high · low Jul 14
Avg volume 20D
748.6K
shares / day
Short interest
5.98M
≈0.9% of shares · −14.5%
Days to cover
8.1
at average volume
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q3 2026: 17 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    14 of 21 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −14.5% to 5.98M shares. 8.1 days to cover, ≈0.9% of shares.

  • TrendUPTREND

    12% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JPMORGAN CHASE & COADD2,430,436$17.7M
UBS Group AGADD2,400,052$17.5M
BARCLAYS PLCADD1,150,168$8.4M
Hudson Bay Capital Management LPDOUBLED1,078,362$7.9M
BNP PARIBAS FINANCIAL MARKETSDOUBLED716,375$5.2M
Verition Fund Management LLCTRIM226,464$1.7M
Quantinno Capital Management LPTRIM128,675$940.6K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED126,691$926.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 67% rate it Buy or better
Strong Buy4Buy10Hold5Sell2Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +19%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 26, 2026JP Morgan
MAINTAIN
MAINTAINNeutral

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next QNoneNoneNo data$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
5,978,971
shares short
-14.5%
vs prior settlement
8.1
days to cover
≈0.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.

SecBot reports

4 filings · 3 press releases · 1 bullish · 0 bearish · 3 neutral
All GRFS filing & press-release reports (7)